AngioDynamics (ANGO) announced the start of a randomized study of the Auryon Atherectomy System used in combination with Standard Balloon Angioplasty versus Standard Balloon Angioplasty alone treating infrapopliteal lesions in subjects with critical limb ischemia below-the-knee.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics Earnings Call Highlights Med Tech Growth
- AngioDynamics Highlights Strategic Growth at Healthcare Conference
- AngioDynamics announces publication of APEX-AV trial results in JSCAI
- AngioDynamics price target raised to $16 from $13 at Oppenheimer
- AngioDynamics price target raised to $15 from $14 at H.C. Wainwright